L Manzino
Overview
Explore the profile of L Manzino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whiteside G, Dwyer J, Harrison J, Beyer C, Cummons T, Manzino L, et al.
Br J Pharmacol
. 2010 Jul;
160(5):1105-18.
PMID: 20590604
Background And Purpose: Antidepressants, which raise the CNS concentrations of 5-HT and noradrenaline, are frequently used in the treatment of chronic pain; however, it is not known if increasing CNS...
2.
Zeevalk G, Manzino L, Sonsalla P, Bernard L
Exp Neurol
. 2006 Oct;
203(2):512-20.
PMID: 17049515
Parkinson's disease (PD) is associated with loss of total glutathione (GSH) which may contribute to progressive cell death. Peripheral GSH administration has been used clinically with reported benefits. Despite this,...
3.
Yazdani U, German D, Liang C, Manzino L, Sonsalla P, Zeevalk G
Exp Neurol
. 2006 Mar;
200(1):172-83.
PMID: 16546169
Mitochondrial dysfunction is observed in sporadic Parkinson's disease (PD) and may contribute to progressive neurodegeneration. While acute models of mitochondrial dysfunction have been used for many years to investigate PD,...
4.
Gluck M, Moy L, Jayatilleke E, Hogan K, Manzino L, Sonsalla P
J Neurochem
. 2001 Oct;
79(1):152-60.
PMID: 11595767
The neurotoxic actions of methamphetamine (METH) may be mediated in part by reactive oxygen species (ROS). Methamphetamine administration leads to increases in ROS formation and lipid peroxidation in rodent brain;...
5.
Zeevalk G, Bernard L, Manzino L, Sonsalla P
J Pharmacol Exp Ther
. 2001 Aug;
298(3):925-33.
PMID: 11504786
Disturbance in phosphorylation/dephosphorylation can trigger apoptosis. Little is known as to its effects on mesencephalic dopamine neurons, the major neurons lost in Parkinson's disease. In this study, okadaic acid (OKA),...
6.
Zeevalk G, Manzino L, Sonsalla P
Exp Neurol
. 2000 Feb;
161(2):638-46.
PMID: 10686083
Defects in energy metabolism have been detected in patients with Parkinson's disease and have been proposed as a contributing factor in the disease. Previous in vitro studies showed that NMDA...
7.
Sonsalla P, Manzino L, Sinton C, Liang C, German D, Zeevalk G
Brain Res
. 1997 Dec;
773(1-2):223-6.
PMID: 9409726
This study examined whether damage to dopamine (DA) nerve terminals via inhibition of energy metabolism in the striatum would result in the retrograde loss of cell bodies in the substantia...
8.
Zeevalk G, Manzino L, Hoppe J, Sonsalla P
Eur J Pharmacol
. 1997 Feb;
320(2-3):111-9.
PMID: 9059843
In vitro studies indicate that mesencephalic dopamine neurons are more vulnerable than other neurons to impairment of energy metabolism. Such findings may have bearing on the loss of dopamine neurons...
9.
Mark M, Sage J, Dickson D, Heikkila R, Manzino L, Schwarz K, et al.
Neurology
. 1994 Aug;
44(8):1432-6.
PMID: 8058144
We report a patient with Meige syndrome (segmental cranial dystonia) who had neuropathologic changes of Parkinson's disease on postmortem examination. Neuropathologic examination showed typical and atypical Lewy bodies in the...
10.
Sonsalla P, Giovanni A, Sieber B, Donne K, Manzino L
Ann N Y Acad Sci
. 1992 May;
648:229-38.
PMID: 1637048
No abstract available.